ECSP10010224A - Formulaciones líquidas de hormona luteinizante (lh). - Google Patents
Formulaciones líquidas de hormona luteinizante (lh).Info
- Publication number
- ECSP10010224A ECSP10010224A EC2010010224A ECSP10010224A ECSP10010224A EC SP10010224 A ECSP10010224 A EC SP10010224A EC 2010010224 A EC2010010224 A EC 2010010224A EC SP10010224 A ECSP10010224 A EC SP10010224A EC SP10010224 A ECSP10010224 A EC SP10010224A
- Authority
- EC
- Ecuador
- Prior art keywords
- luteinizing hormone
- liquid formulations
- hormone liquid
- administration
- luteinizing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere a formulaciones farmacéuticas líquidas de hormona luteinizante (LH) para administración en una sola dosis o en múltiples dosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07119832 | 2007-11-01 | ||
US448107P | 2007-11-28 | 2007-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP10010224A true ECSP10010224A (es) | 2010-07-30 |
Family
ID=39167502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2010010224A ECSP10010224A (es) | 2007-11-01 | 2010-05-31 | Formulaciones líquidas de hormona luteinizante (lh). |
Country Status (26)
Country | Link |
---|---|
US (1) | US8664369B2 (es) |
EP (1) | EP2219607B1 (es) |
JP (1) | JP5551601B2 (es) |
KR (1) | KR101513181B1 (es) |
CN (1) | CN101842083B (es) |
AU (1) | AU2008320844B2 (es) |
BR (1) | BRPI0818324B8 (es) |
CA (1) | CA2700662C (es) |
CY (1) | CY1113121T1 (es) |
DK (1) | DK2219607T3 (es) |
EA (1) | EA019432B1 (es) |
EC (1) | ECSP10010224A (es) |
ES (1) | ES2393233T3 (es) |
HK (1) | HK1145443A1 (es) |
HR (1) | HRP20120660T1 (es) |
IL (1) | IL205105A (es) |
MX (1) | MX2010004639A (es) |
MY (1) | MY153976A (es) |
NZ (1) | NZ583991A (es) |
PL (1) | PL2219607T3 (es) |
PT (1) | PT2219607E (es) |
RS (1) | RS52566B (es) |
SI (1) | SI2219607T1 (es) |
UA (1) | UA101484C2 (es) |
WO (1) | WO2009056569A1 (es) |
ZA (1) | ZA201001907B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2524423C2 (ru) | 2008-01-09 | 2014-07-27 | Санофи-Авентис Дойчланд Гмбх | Новые производные инсулина с чрезвычайно замедленным профилем время/действие |
RS59913B1 (sr) | 2008-10-17 | 2020-03-31 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
JP2011001273A (ja) * | 2009-06-16 | 2011-01-06 | Eci Inc | eMIPを有効成分とする水溶性製剤 |
CN105535943A (zh) * | 2009-07-06 | 2016-05-04 | 赛诺菲-安万特德国有限公司 | 含有甲硫氨酸的水性胰岛素制备物 |
KR101972301B1 (ko) | 2009-11-13 | 2019-04-25 | 사노피-아벤티스 도이칠란트 게엠베하 | Glp-1 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물 |
BR112012011403B8 (pt) | 2009-11-13 | 2021-05-25 | Sanofi Aventis Deutschland | composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma |
RU2553375C2 (ru) * | 2010-02-12 | 2015-06-10 | Интас Биофармасьютикалс Лимитед | Жидкий состав фолликулостимулирующего гормона |
CA2809321C (en) | 2010-08-30 | 2018-08-14 | Sanofi-Aventis Deutschland Gmbh | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
CN102293756A (zh) * | 2011-08-24 | 2011-12-28 | 蚌埠丰原涂山制药有限公司 | 一种尿促性素冻干粉针剂及其制备方法 |
HUE027989T2 (en) | 2011-08-29 | 2016-11-28 | Sanofi Aventis Deutschland | A pharmaceutical composition for use in glycemic control in patients with type 2 diabetes |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
JP2016505601A (ja) * | 2012-12-26 | 2016-02-25 | ウォックハート リミテッド | 医薬組成物 |
TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
WO2015104314A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
AU2015205621A1 (en) | 2014-01-09 | 2016-07-14 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
AU2015205620A1 (en) | 2014-01-09 | 2016-07-14 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
SI3229828T1 (sl) | 2014-12-12 | 2023-06-30 | Sanofi-Aventis Deutschland Gmbh | Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
GB201603280D0 (en) * | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE64738B1 (en) * | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
IT1250075B (it) * | 1991-12-18 | 1995-03-30 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti gonadotropine. |
US5681302A (en) * | 1994-06-14 | 1997-10-28 | Minnesota Mining And Manufacturing Company | Elastic sheet-like composite |
JP4165718B2 (ja) * | 1995-03-21 | 2008-10-15 | ラボラトワール セローノ ソシエテ アノニム | hCG液体製剤 |
IL122732A0 (en) * | 1997-01-15 | 1998-08-16 | Akzo Nobel Nv | Liquid gonadotropin-containing formulation its preparation and a device containing same |
NZ508874A (en) * | 1998-07-23 | 2004-03-26 | Lilly Co Eli | FSH and FSH variant formulations, products and methods of treating infertility. |
WO2004062689A1 (en) * | 2003-01-08 | 2004-07-29 | Chiron Corporation | Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant |
US7387998B2 (en) | 2003-03-28 | 2008-06-17 | New York University | STQ peptides |
KR101105486B1 (ko) * | 2003-04-02 | 2012-01-13 | 아레스 트레이딩 에스.에이. | Fsh 및 lh과 비이온성 계면활성제의 액상 약제학적 제제 |
-
2008
- 2008-10-29 PL PL08844750T patent/PL2219607T3/pl unknown
- 2008-10-29 US US12/681,688 patent/US8664369B2/en active Active
- 2008-10-29 ES ES08844750T patent/ES2393233T3/es active Active
- 2008-10-29 KR KR1020107012131A patent/KR101513181B1/ko active IP Right Grant
- 2008-10-29 MY MYPI2010001950A patent/MY153976A/en unknown
- 2008-10-29 RS RS20120484A patent/RS52566B/en unknown
- 2008-10-29 UA UAA201006712A patent/UA101484C2/ru unknown
- 2008-10-29 AU AU2008320844A patent/AU2008320844B2/en active Active
- 2008-10-29 NZ NZ583991A patent/NZ583991A/en unknown
- 2008-10-29 EP EP08844750A patent/EP2219607B1/en active Active
- 2008-10-29 CN CN2008801145250A patent/CN101842083B/zh active Active
- 2008-10-29 DK DK08844750.3T patent/DK2219607T3/da active
- 2008-10-29 CA CA2700662A patent/CA2700662C/en not_active Expired - Fee Related
- 2008-10-29 BR BRPI0818324A patent/BRPI0818324B8/pt active IP Right Grant
- 2008-10-29 WO PCT/EP2008/064679 patent/WO2009056569A1/en active Application Filing
- 2008-10-29 MX MX2010004639A patent/MX2010004639A/es active IP Right Grant
- 2008-10-29 EA EA201070549A patent/EA019432B1/ru not_active IP Right Cessation
- 2008-10-29 SI SI200830735T patent/SI2219607T1/sl unknown
- 2008-10-29 JP JP2010531519A patent/JP5551601B2/ja active Active
- 2008-10-29 PT PT08844750T patent/PT2219607E/pt unknown
-
2010
- 2010-03-17 ZA ZA2010/01907A patent/ZA201001907B/en unknown
- 2010-04-15 IL IL205105A patent/IL205105A/en active IP Right Grant
- 2010-05-31 EC EC2010010224A patent/ECSP10010224A/es unknown
- 2010-12-20 HK HK10111880.8A patent/HK1145443A1/xx unknown
-
2012
- 2012-08-15 HR HRP20120660AT patent/HRP20120660T1/hr unknown
- 2012-09-13 CY CY20121100836T patent/CY1113121T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP10010224A (es) | Formulaciones líquidas de hormona luteinizante (lh). | |
AR124134A2 (es) | Formulación de uso tópico para un inhibidor de jak | |
BR112016000194A8 (pt) | forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila | |
UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
DK2010190T3 (da) | Farmaceutisk opløsningsformulering til tryksatte, dosisregulerede inhalatorer | |
GT200600445A (es) | Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo. | |
BRPI0606339A2 (pt) | formas farmacêuticas resistentes a álcool | |
AR054595A1 (es) | Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis | |
CR11418A (es) | Trans-clomifeno para el sindrome metabolico | |
CL2011002858A1 (es) | Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor. | |
GT201400059A (es) | Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos | |
AR070026A1 (es) | Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus | |
PE20090607A1 (es) | Formulacion farmaceutica de dispersion liposomal en polvo seco | |
EA201400737A1 (ru) | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества | |
EA201170512A1 (ru) | Композиция для перорального введения | |
CR20110704A (es) | Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amilodipina, su preparación y su aplicación terapéutica | |
TN2015000135A1 (en) | Modified release formulations for oprozomib | |
EA201391689A1 (ru) | Система доставки лекарственного средства | |
CL2015002466A1 (es) | Formulaciones de compuestos orgánicos | |
EA201200485A1 (ru) | Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол | |
IT1401284B1 (it) | Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system). | |
ECSP088850A (es) | Formulación de medicamento líquida | |
CL2016000183A1 (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
AR061046A1 (es) | Mirtazapina para el tratamiento del dolor neuropatico | |
UY35784A (es) | Formas farmacéuticas de dosificación que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h- 1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio |